Jeff Geschwind Innovating the Fight Against Cancer Across Sectors

Jeff Geschwind is a name synonymous with progress in oncology and medical innovation. With an illustrious career spanning several organizations and domains, he is actively transforming the landscape of cancer care in the United States and beyond. Currently, he holds five critical roles that place him at the intersection of clinical oncology, medical research, therapeutic development, and healthcare technology.

At the helm of clinical oncology at USA Clinics Group, Jeff Geschwind serves as the Director of Oncology. Here, he oversees the implementation of advanced treatment protocols, particularly focusing on minimally invasive, image-guided techniques. USA Clinics Group, known for its emphasis on patient-centered care, benefits greatly from Dr. Geschwind’s vast knowledge in interventional oncology—a field where he has made a lasting impact through years of clinical practice and research.

His influence extends further into the research sphere as the Medical Director for Oncology, Image-Guided Therapy, and Imaging Core Lab at NAMSA. NAMSA is one of the largest contract research organizations in the U.S., with a reputation for accelerating the development of life-saving medical products. In this leadership role, Dr. Geschwind guides the oncology arm of NAMSA’s operations, ensuring rigorous clinical standards are met and supporting the development and testing of groundbreaking therapies and medical devices. Based in New York City, NAMSA has become a nexus of collaboration between researchers, clinicians, and innovators—largely due to the influence of professionals like Dr. Geschwind.

But his commitment to defeating cancer is not limited to traditional medical practice or research administration. As Medical Advisor for HistoSonics, he contributes to the development of one of the most promising non-invasive therapies for liver cancer. HistoSonics is pioneering histotripsy, a novel technology that employs focused ultrasound energy to destroy cancer cells without surgery, chemotherapy, or radiation. This approach is not only non-invasive but also highly precise, minimizing damage to healthy tissue and reducing recovery time. Dr. Geschwind’s role is to bridge the gap between clinical practice and device innovation—ensuring that HistoSonics' technology meets real-world medical needs.

In addition to working with established organizations, Jeff Geschwind is also a successful entrepreneur. In 2009, he founded PreScience Labs, which has since evolved into Cage Pharma. This company is focused on an area of cancer biology that is often overlooked—tumor metabolism. Specifically, Cage Pharma targets glycolysis, the metabolic pathway that cancer cells hijack to fuel their rapid growth. By disrupting this process, the company aims to halt cancer at the biochemical level, potentially enhancing the effectiveness of existing treatments and overcoming resistance to traditional therapies. Dr. Geschwind’s founding vision for Cage Pharma remains at the core of its operations, and his continued consultancy ensures the scientific integrity and strategic direction of its research.

Lastly, Dr. Geschwind lends his expertise to Philips Healthcare, where he acts as a scientific consultant. Philips is a global leader in medical imaging and health technology, and Dr. Geschwind’s input is invaluable in shaping the company’s oncology and image-guided therapy initiatives. With his guidance, Philips is developing tools that improve the accuracy of diagnosis, optimize treatment plans, and ultimately improve patient outcomes.

What makes Jeff Geschwind truly exceptional is his holistic approach to cancer care. He does not limit himself to a single perspective—be it clinical, academic, entrepreneurial, or technological. Instead, he works across all these domains to promote synergy and integration in cancer treatment strategies. Whether he is overseeing treatment protocols at USA Clinics Group, guiding research at NAMSA, contributing to the development of non-invasive cancer therapies at HistoSonics, pioneering new drug strategies at Cage Pharma, or influencing imaging solutions at Philips, his contributions are unified by a mission to innovate and improve lives.

As oncology continues to evolve rapidly with the integration of AI, personalized medicine, and non-invasive techniques, professionals like Jeff Geschwind are critical. His career reflects not only a deep understanding of cancer and its complexities but also a rare ability to connect disciplines in meaningful ways. His work ensures that innovation does not remain in laboratories but translates into real-world solutions that benefit patients today and for generations to come.